Kura Oncology (KURA) Total Non-Current Liabilities (2014 - 2026)

Kura Oncology (KURA) has 13 years of Total Non-Current Liabilities data on file, last reported at $541.2 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 43.48% year-over-year to $541.2 million in Q1 2026; TTM through Mar 2026 was $541.2 million, a 43.48% increase from a year earlier, with the FY2025 full-year figure at $561.1 million, up 62.76% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $541.2 million, down from $561.1 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for KURA reached as high as $561.1 million in Q4 2025 and fell as low as $21.5 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $177.5 million across 5 years, with a median of $47.9 million in 2024.
• Across the five-year window, Total Non-Current Liabilities slumped 35.45% in 2022 and soared 687.96% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $35.8 million in 2022, then jumped by 42.49% to $51.0 million in 2023, then surged by 576.5% to $344.7 million in 2024, then surged by 62.76% to $561.1 million in 2025, then slipped by 3.53% to $541.2 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $541.2 million in Q1 2026, $561.1 million in Q4 2025, and $403.9 million in Q3 2025.